High-Frequency, Low-Dose Calquence-Rituxan Combo May Elicit Safe Responses in Previously Untreated CLL/SLLArticle
CURE,
Calquence (acalabrutinib) and Rituxan (rituximab) given at a high frequency and low dose demonstrated to be tolerable and…
Calquence (acalabrutinib) and Rituxan (rituximab) given at a high frequency and low dose demonstrated to be tolerable and…
Patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who were treated with high-frequency low-dose…
High-frequency low-dose acalabrutinib and rituximab represents a feasible and effective combination for the treatment of…